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(78.8%), retinopathy (27.9%) and nephropathy (22.2%); Indian were highest in PVD 
(26.8%), and CAD (34.4%); Chinese highest in stroke (12.1%). After adjusting for 
age, gender and ethnicity, the odds of having “optimal” glycemic control was higher 
for T2DM patients with nephropathy (Adj OR:1.50; 95% CI [1.19–1.89]) and stroke 
(Adj OR:1.51; 95% CI [1.17–1.96]) compared to PVD (Adj OR: 0.61; 95% CI 
[0.51–0.74]) and retinopathy (Adj OR: 0.65; 95% CI [0.53–0.79]). CONCLUSIONS: 
There were ethnic differences in the prevalence of diabetes-related complications. 
T2DM patients with stroke or nephropathy were more likely to achieve “optimal” 
HbA1c level than those with PVD or eye complications. 
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OBJECTIVES: Health technology Assessment (HTA) has a long history in Australia and 
NZ and is rapidly evolving in Asian countries. The aim of this research was to identify 
and review English written reports on diabetes among HTA agencies in Asia and 
Oceania. METHODS: ISPORs directory (http://www.ispor.org) listing worldwide HTA 
organizations were searched for agencies in Asia and Oceania with a valid link to a 
webpage were included. On each agencies webpage a search was done using the search 
term “diabetes” and English written assessments were included for further review. 
RESULTS: The following HTA agencies were searched: PBAC, MSAC ASERNIP-S, 
AHTA, CCE, CHERE, HTA, NIPH, CRECON, MAPI, PHIC, PKEBM, ICTACH, 
HSAC, NZHTA, HIRA, CDE and HITAP. Of those, only 14 relevant reports were 
found from Australia, NZ and Thailand. Two were found from PBAC, ﬁ ve from AHTA, 
one from HSAC, two from NZHTA, and four from HITAP. The two reports from PBAC 
were describing how to improve National management of diabetes. The reports from 
AHTA were horizon scanning reports covering glucose monitoring, screening of gesta-
tional diabetes and detecting retinopathy. HSAC had a report on insulin pump whereas 
as NZHTA had one on glucose monitoring and one about clinical features detecting 
insulin resistance. The reports found on HITAP were in the form of published articles 
assessing cost effectiveness of two different antihypertensive therapies in diabetes, one 
assessing cost effectiveness of diabetes management and ﬁ nally one assessing diabetes 
self management. Reports from HSAC, NZHTA and HITAP contained economic 
modeling with QALY as outcome. CONCLUSIONS: Despite of broad search criteria 
only 14 English written reports were found on diabetes. A headline in English on each 
assessment would facilitate information sharing and make it easier to evaluate the need 
for translational support. 
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OBJECTIVES: Due to the effect of National Health Insurance drug price cut policy, 
the studied hospital has changed the manufactures of metformin four times in 5 years 
since July, 2004. The purpose of this study is to investigate the effects of the change 
in hospital drug brands on patients’ utilization and the factors that inﬂ uence patients’ 
persistence on the use of metformin. METHODS: Data were sourced from a medical 
center in Taipei city during 2004–2008. We collected all the oral antidiabetic drugs 
used during the study period and classiﬁ ed them into ﬁ ve categories: Biguanid, Sulfo-
nylures, α-glucosidase inhibitor, Thiazolidinediones, and Meglitinide. The quantity of 
all the antidiabetics used was transformed by using WHO/ATC into DDDs. In this 
study, Metformin was treated as the experimental group and all other antidiabetics 
drugs were the control groups. RESULTS: The results showed that the quantity of 
metformin prescribed was increasing during the study period in spite of the brand 
change. However, other categories of oral antidiabetes were also increasing due to the 
increase in number of patients. The percentage of all types of drug stayed relatively 
steadily, in which metformin itself occupied 21–23%, all Sulfonylureas drugs occupied 
59–60%, α-glucosidase inhibitor occupied 3–4%, Thiazolidinediones occupied 
10–11%, and Meglitinide occupied 4–5% during the study period. In addition, the 
results of logistic regressions showed that female patients with hypertension or hyper-
lipemia between the ages of 40~80 who live in Taipei city performed better persistence 
of seeking medical service. CONCLUSIONS: The results shows changing the brand 
of metformin did not decrease drug consumption and patient numbers. By analyzing 
the acceptance of generic drugs of patients and doctors, this study provides important 
information for hospital administrators and health administrators. 
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OBJECTIVES: To explore current disease status and approach to care for patients 
with type 2 diabetes (T2DM) in China. METHODS: The study was performed using 
data from the Adelphi T2DM Disease Speciﬁ c Programme (DSP©), a cross-sectional 
study of consulting patients providing insights into “real-world” behaviors and atti-
tudes in clinical practice in 2008. The DSP collected data on 1648 patients with T2DM 
receiving at least one oral anti-diabetic with or without insulin and from 200 physi-
cians (140 specialists and 60 internal medicine) across general hospitals in nine 
Chinese cities through physician interviews, patient record forms and patient-
completed questionnaires. RESULTS: Of 1648 patients (50% male, mean [SD] age: 
57.74 [12.56] years, BMI: 24.04 [3.37] kg/m2, duration of diabetes: 4.52 [5.06] years), 
74% had at least one comorbidity, 39% were overweight (24 ≤ BMI < 28 kg/m2) and 
9% were obese (BMI ≥ 28 kg/m2). Sixty-one percent had an HbA1c ≥ 7% and only 
35% of patients were aware of an HbA1c target. 39.20% of patients were treated 
with OAD monotherapy (metformin [Met]: 12.26%, Sulphonyureas [SU]: 12.56%, 
alpha-glucosinase inhibitor [AGI]: 8.37%, prandial glucose regulators [PGR]: 4.67%, 
thiazolidinediones [TZD]: 2.31%) and 29.67% were on dual OAD therapy (com-
monly Met + SU: 11.71%, Met + AGI: 4.37%, SU + AGI: 3.82%, Met + PGR: 4.25%, 
Met + TZD: 1.52%), while 28.09% of patients were on OAD + insulin therapy. Lack 
of gastrointestinal, liver function side effects and hypoglycemia risk, QD dosage, and 
beneﬁ cial effects on blood pressure were the ﬁ ve most cited unmet needs in non-insulin 
diabetes treatment highlighted by physicians. Mean (SD) patient-reported QoL 
(EQ-5D VAS) was 0.86 (0.18) and mean (SD) diabetes treatment satisfaction was 
25.97(5.14)/36 where 0 is very dissatisﬁ ed and 36 very satisﬁ ed. CONCLUSIONS: 
The study population of Chinese T2DM patients is relatively young and recently 
diagnosed. More than half were poorly controlled and the need for further therapeutic 
actions to improve glycemic control as well as better doctor/patient communication 
regarding treatment goals is clear. 
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OBJECTIVES: Examine BMI and achievement of diabetes treatment targets in patients 
with Type 2 Diabetes (T2DM). METHODS: The study used the 2008 Adelphi T2DM 
Disease Speciﬁ c Programme© a cross-sectional study of consulting patients providing 
insights into ‘real-world’ behaviors and attitudes in clinical practice. Data was col-
lected on 1648 patients with T2DM receiving at least one oral anti-diabetic with/
without insulin and 140 specialists and 60 internal medicine physicians distributed 
across general hospitals in nine Chinese cities through physician interviews, patient 
record forms and self-completed questionnaires. RESULTS: Across the 1648 patients 
in the study; mean (SD) age was 57.7 (12.6) years, 46% were ≤2 years from diagnosis 
and mean (SD) BMI was 24.0 (3.4) kg/m2. Nine percent of patients were obese (BMI 
≥ 28 kg/m2), 39% overweight (24 ≤ BMI < 28 kg/m2) and 51% normal/underweight 
(BMI < 24 kg/m2). Prevalence of comorbidities in this population was high; 49% 
reporting hypertension and 42% dyslipidemia (25% patients reported both). Glycemic 
control appeared worse in patients with a higher BMI. Twenty-two percent of patients 
with a BMI ≥ 28 had an HbA1c ≥ 9% and 39% had an HbA1c ≥ 8% compared to 
10% of patients with a BMI between 19–27.9 having an HbA1c ≥ 9% and 22% 
having an HbA1c ≥ 8%. Only 35% of patients were aware of having an HbA1c target 
set by their physician. Comorbid conditions were more prevalent in overweight and 
obese patients. Among normal weight patients 31% reported no comorbid conditions 
compared to 22% of overweight patients and 17% of obese patients. Prevalence of 
hypertension, dyslipidemia and other macrovascular conditions were 44%, 36%, and 
18% respectively among normal weight patients; 53%, 48%, and 19% among over-
weight patients and 65%, 55%, and 24% among obese patients. CONCLUSIONS: 
The results indicate that obese patients report higher HbA1c and higher rates of 
complications compared to the normal weight patients and strategies to improve target 
better outcomes could include managing obesity. 
GASTROINTESTINAL DISORDERS – Clinical Outcomes Studies
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OBJECTIVES: An objective of this review was to assess clinical efﬁ cacy in terms of 
“HBeAg seroconversion” of treatment options for HBeAg-positive chronic hepatitis 
B (CHB). METHODS: A systematic review of randomized controlled trials (RCTs) of 
treatments for patients with HBeAg-positive CHB was performed through the Medline 
and Cochrane databases. The clinical studies were included only if they assessed the 
efﬁ cacy among the following treatment options namely 1) lamivudine; 2) entecavir; 
3) interferon; and 4) interferon plus lamivudine. Indirect or mixed-treatment compari-
son meta-analysis with random effect model was employed to combine results of 
several studies. The meta-analysis was carried out using the WinBUGS14 software. 
Odds ratio (OR) and its 95% conﬁ dence interval (CI) were presented. Heterogeneity 
test was applied for testing the variation of study outcomes between studies. RESULTS: 
There were 115 abstracts reviewed with eight relevant RCTs included in the analysis. 
None of eight RCTs included all four treatment options. Five studies compared HBeAg 
seroconversion between entecavir and lamivudine. There were three different studies 
comparing interferon with interferon plus lamivudine, interferon plus lamivudine with 
lamivudine, and interferon and interferon plus lamivudine with lamivudine. Indirect 
A532 4th Asia-Paciﬁ c Abstracts
comparison was applied to compare entecavir with interferon and the combination of 
interferon and lamivudine. When compared with lamivudine, the combination of inter-
feron and lamivudine yielded the best efﬁ cacy which was about two times more likely to 
increase HBeAg seroconversion rate (OR = 2.38, 95% CI = 1.21–4.06) than entecavir 
(OR = 0.98, 95% CI = 0.56–1.44) and interferon (OR = 1.17, 95% CI = 0.44–2.24). In 
addition, when compared with either interferon or entecavir, interferon plus lamivudine 
was about two to three times more likely to enhance HBeAg seroconversion rate with the 
OR of 2.48 (95% CI = 1.05–4.92) or 2.71 (95% CI = 1.13–5.33), respectively. CONCLU-
SIONS: There was a signiﬁ cant increase in HBeAg seroconversion rate in patients with 
HBeAg positive CHB receiving the combination of interferon and lamivudine com-
pared with lamivudine, entecavir and interferon. 
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EFFECTIVENESS AND COST ANALYSIS OF PARENTERNAL REGIMEN IN 
CRITICAL ILLNESS PATIENTS OF POSTOPERATIVE: THREE-
COMPARTMENT BAG SYSTEM AND TRANDITIONAL SEPARATE BOTTLE 
SYSTEM
Hsieh HJ, Chan AL
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OBJECTIVES: To evaluate clinical outcome and direct medical cost using Kabiven 
and traditional peripheral partenteral nutrition for postoperative patients in ICU. 
METHODS: This is a restrospective study. Medical records of postoperative patients 
in ICU were reviewed by clinical pharmacists from July 2008 to July 2009. The 
retrieved patients were divided into two groups, kabiven group (n = 49) and separate 
bottle group (SB) (n = 50). Patients, characteristics were evaluated and compared 
between two groups. The measured outcomes were the clinical effectiveness and direct 
medical costs. One way ANOVA were used for analysis. RESULTS: There were no 
statistically signiﬁ cance difference in patients, characteristics between two groups. 
Survival rate was higher in kabiven group than in SB group (40% vs. 31%, respec-
tively). The length of stay in hospital in kabiven group was longer than in SB group 
(47.51 ± 38.63 vs. 31.86 ± 21.99 days, respectively; P < 0.015). Total direct medical 
costs of survivors in kabiven group was more expensive than in SB group ($11,976.9 
vs. $9574.9, respectively). CONCLUSIONS: Although the direct medical cost of 
kabiven group were higher than SB group, use of kabiven is likely to improve mortality 
rate of postoperative patients in ICU. 
GASTROINTESTINAL DISORDERS – Cost Studies
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OBJECTIVES: Heptatitis B is prevalent in South Korea and chronic hepatitis B (CHB) 
infection is an important public health issue due to its potential to evolve to cirrhosis, 
hepatocellular carcinoma. This study estimated the direct medical cost of CHB-related 
disease states in South Korea and compared the cost of South Korea with that of USA, 
Australia and China. It also aimed to analyze the impact of three therapeutic alterna-
tives for CHB by Budget Impact Analysis (BIA). METHODS: Dynamic budget impact 
analysis was conducted based on a Markov model for 5 years. Three treatment sce-
narios were selected as follows: ﬁ rst-line treatment of lamivudine, second-line combi-
nation treatment of lamivudine and adefovir on the development of drug resistance, 
ﬁ rst-line treatment of lamivudine, second-line treatment of entecavir 1.0 mg on the 
development of drug resistance, ﬁ rst-line treatment of entecavir 0.5 mg, second-line 
treatment of adefovir on the development of drug resistance, no treatment available. 
RESULTS: The BIA results of scenario A, B, C and no treatment were 75, 74.7, 85.9, 
and 48.1 billion Korean Won (KRW), respectively. The results were relatively insensi-
tive to the TP and sensitive to the number of treated patients based on sensitivity 
analyses. The costs of annual direct medical costs in South Korea were 23.2%~65.8%, 
16.2%~59.1%, and 75.8%~381.7% of the annual direct medical costs in the United 
States, Australia, and China. CONCLUSIONS: Scenario C (ﬁ rst-line treatment of 
entecavir 0.5 mg, second-line treatment of adefovir) was found to be 10.9~11.2 billion 
KRW more expensive than scenario A and B from payer’s perspective. In South Korea, 
the direct medical costs of CHB-related diseases are cheaper than the United States 
and Australia. It suggests that such factors as the difference of GNP (Gross National 
Product), health-care system and others contribute to the difference of the direct 
medical costs. 
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OBJECTIVES: Our objective was to compare cost saving before and after of pharma-
ceutical care implementation and Octreotide use evaluation at surgical ward. 
METHODS: This study was conducted during October 1, 2008 to April 30, 2009. The 
research instruments were octreotide use criteria with approval by surgical staffs. Phar-
macist reviewed and evaluated the medical chart in order to identify medication related 
problems by focusing on medication regimens. Medication related problems were clas-
siﬁ ed into three categories: inappropriate route, inappropriate duration and inappropri-
ate indication of administration. Cost saving was based on drug costs. The pre- and 
post-pharmaceutical care implementation and octreotide use evaluation results were 
compared and analyzed with descriptive retrospective statistics and paired t–test at 95 
% signiﬁ cant level. RESULTS: There were 302 patients received Octreotide. One 
hundred ninety-three patients (63.9%) were prescribed Octreotide appropriately. Medi-
cation related problems were found in 109 patients (36.1%). The most frequent prob-
lems were inappropriate duration (44.95%), inappropriate indication (34.86%) and 
inappropriate route of administration (20.18%). The cost of Octreotide use for inap-
propriate duration, inappropriate indication and inappropriate route of administration 
were signiﬁ cantly decreased after pharmaceutical care implementation 3,062,160 versus 
1,946,400 baht, 657,000 versus no money, and 919,800 versus 226,800 baht, respec-
tively (P < 0.005). The total cost of Octreotide use was 9,529,950 baht reducing to 
7,015,008 baht after pharmaceutical care implementation with statistically signiﬁ cant 
(P < 0.005). CONCLUSIONS: The implementation of pharmaceutical care and evalu-
ation of Octreotide use resulted in signiﬁ cant cost saving. The drug utilization 
program, consisting of deriving quality criteria for prescribing, structured order form 
and good cooperation between physicians and pharmacists with strong support of the 
therapeutics committee, was an effective strategic approach to promote rational drug 
use and develop Octreotide use guidelines. 
GASTROINTESTINAL DISORDERS – Patient-Reported Outcomes Studies
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THE EFFECT OF ANTIVIRAL THERAPY ON QUALITY OF LIFE IN 
CHRONIC HEPATITIS PATIENTS: A SYSTEMATIC REVIEW
Pansang S, Maphanta S
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OBJECTIVES: Chronic viral hepatitis B and C are treated primarily with interferon 
(IFN) and/or nucleotide analogs e.g., ribavirin (RBV) which produced sustained viral 
response in more than 50% of treated patients. However, the combination may also 
cause numerous side effects that could reduce patients’ quality of life (QoL). To 
determine the effect of antiviral therapy on QoL of chronic hepatitis patients. 
METHODS: Key words were “Quality of life” AND “chronic hepatitis” AND “anti-
viral therapy,” “lamivudine,” “ribavirin,” “adefovir,” “entacavir,” “telbivudine” 
“tenofovir” and were searched from PubMed and EMBASE database. Study selection 
criteria were original articles in which patients received antivirals for chronic hepatitis 
B or C, and assessed QoL. The comparators were no treatment, placebo or at least 
one other antiviral. Studies that involved co-HIV infection were excluded. One inde-
pendent researcher reviewed titles and abstracts to determine relevance. Study design, 
dose, duration, baseline values, and QoL scores were extracted. RESULTS: Six studies 
met all the criteria. Four QoL instruments were used in those studies. SF 36 and 
HQLQ questionnaires were the most common. Patients who received peginterferonμ-
2a plus placebo reported better QoL than peginterferonμ-2a plus ribavirin during the 
treatment (week 2–48) in two RCTs. However, the results were less consistent and 
less prominent during the week of 72 and 96. The effect seemed to be non-dose related. 
One RCT showed that interferon μ plus ribavirin produced better QoL than untreated 
when measured with EQ 5D questionnaire, but it did not reach statistical signiﬁ cant. 
In similarly, peginterferone μ-2a plus ribavirin did not showed a signiﬁ cant better 
Fatigue severity scale at week 72 when compared with peginterferonμ-2a plus placebo. 
CONCLUSIONS: Antiviral therapy (interferon plus ribavirin) reduced QoL only 
during the treatment. Results seemed to be consistent across all four types of QoL 
questionnaires. 
GASTROINTESTINAL DISORDERS – Health Care Use & Policy Studies
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OBJECTIVES: This study was conducted to obtain information on current prescribing 
rates of antibiotics in diarrhea, a condition where misuse of antibiotics is common. 
In the absence of community-based databases on antibiotic use in developing countries 
recently a methodology was established for surveillance of antibiotic use at New Delhi 
by conducting ‘Exit Interviews’ of the patients. METHODS: Antibiotic use data was 
collected from public and private sector facilities from four residential localities 
around a tertiary care hospital where the antibiotic resistance work was being con-
ducted. All the 10 public sector facilities (eight primary and two secondary health 
cares) situated in the study area under Delhi government were enrolled. For private 
sector, 20 willing and cooperative general practitioners and specialists practicing in 
the chosen areas were selected. Patients after consultation with prescriber were asked 
if they had diarrhea but without blood. Patients with diarrhea were enrolled for exit 
interview and his/her prescription was monitored. Antibiotic use data was collected 
per month over 1 year (December 2007–November 2008). The percentage of patients 
receiving antibiotic and pattern of consumption for various antibiotics was analyzed. 
RESULTS: At public facilities 43% (171/398) and at private facilities 69% (76/110) 
of patients with diarrhea were prescribed at least one antibiotic. Main antibiotic class 
that was prescribed in public and private sector was ﬂ uoroquinolones (89% and 94%); 
